nach oben

Journal of Endocrinological Investigation

Erschienen in:

10.04.2023 | Original Article

Prevalence, risk factors and evolution of diabetes mellitus after treatment in primary aldosteronism. Results from the SPAIN-ALDO registry

verfasst von: M. Araujo-Castro, M. Paja Fano, B. Pla Peris, M. González Boillos, E. Pascual-Corrales, A. M. García Cano, P. Parra Ramírez, P. Martín Rojas-Marcos, J. G. Ruiz-Sanchez, A. Vicente Delgado, E. Gómez Hoyos, R. Ferreira, I. García Sanz, M. Recasens Sala, R. Barahona San Millan, M. J. Picón César, P. Díaz Guardiola, C. M. Perdomo, L. Manjón Miguélez, R. García Centeno, J. C. Percovich, Á. Rebollo Román, P. Gracia Gimeno, C. Robles Lázaro, M. Morales-Ruiz, M. Calatayud Gutiérrez, S. A. Furio Collao, D. Meneses, M. A. Sampedro Nuñez, V. Escudero Quesada, E. Mena Ribas, A. Sanmartín Sánchez, C. Gonzalvo Diaz, C. Lamas, R. Guerrero-Vázquez, M. del Castillo Tous, J. Serrano Gotarredona, T. Michalopoulou Alevras, E. M. Moya Mateo, F. A. Hanzu

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 11/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the prevalence, risk factors and evolution of diabetes mellitus (DM) after targeted treatment in patients with primary aldosteronism (PA).

Methods

A retrospective multicenter study of PA patients in follow-up at 27 Spanish tertiary hospitals (SPAIN-ALDO Register).

Results

Overall, 646 patients with PA were included. At diagnosis, 21.2% (n = 137) had DM and 67% of them had HbA1c levels < 7%. In multivariate analysis, family history of DM (OR 4.00 [1.68–9.53]), the coexistence of dyslipidemia (OR 3.57 [1.51–8.43]) and advanced age (OR 1.04 per year of increase [1.00–1.09]) were identified as independent predictive factors of DM. Diabetic patients were on beta blockers (46.7% (n = 64) vs. 27.5% (n = 140), P < 0.001) and diuretics (51.1% (n = 70) vs. 33.2% (n = 169), p < 0.001) more frequently than non-diabetics. After a median follow-up of 22 months [IQR 7.5–63.0], 6.9% of patients developed DM, with no difference between those undergoing adrenalectomy and those treated medically (HR 1.07 [0.49–2.36], p = 0.866). There was also no significant difference in the evolution of glycemic control between DM patients who underwent surgery and those medically treated (p > 0.05).

Conclusion

DM affects about one quarter of patients with PA and the risk factors for its development are common to those of the general population. Medical and surgical treatment provides similar benefit in glycemic control in patients with PA and DM.

Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H et al (2016) The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101:1889–1916. https://doi.org/10.1210/jc.2015-4061CrossRefPubMed

Conn JW (1965) Hypertension, the potassium ion and impaired carbohydrate tolerance. N Engl J Med 273:1135–1143. https://doi.org/10.1056/NEJM196511182732106CrossRefPubMed

Akehi Y, Yanase T, Motonaga R, Umakoshi H, Tsuiki M, Takeda Y et al (2019) High prevalence of diabetes in patients with primary aldosteronism (PA) associated with subclinical hypercortisolism and prediabetes more prevalent in bilateral than unilateral PA: a large. Multicenter Cohort Study in Japan 42:938–945

Adler GK, Murray GR, Turcu AF, Nian H, Yu C, Solorzano CC et al (2020) Primary Aldosteronism decreases insulin secretion and increases insulin clearance in humans. Hypertens (Dallas Tax 1979) 75:1251–1259. https://doi.org/10.1161/HYPERTENSIONAHA.119.13922CrossRef

Classification and Diagnosis of Diabetes (2022) Standards of medical care in diabetes-2022. Diabetes Care 45:S17-38. https://doi.org/10.2337/DC22-S002CrossRef

Chen W, Li F, He C, Zhu Y, Tan W (2014) Elevated prevalence of abnormal glucose metabolism in patients with primary aldosteronism: a meta-analysis. Ir J Med Sci 183:283–291. https://doi.org/10.1007/S11845-013-1007-XCrossRefPubMed

Muscelli EO, Saad MJ, Gontijo JA (1990) Insulin resistance in essential hypertension. Braz J Med Biol Res 23:1253–1257. https://doi.org/10.1056/nejm198708063170605CrossRefPubMed

Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M et al (2006) Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 91:454–459. https://doi.org/10.1210/jc.2005-1733CrossRefPubMed

Zhang C, Jiang Y, Su T, Jiang L, Zhou W, Zhong X et al (2022) Newly diagnosed diabetes mellitus is a risk factor for cardiocerebrovascular events in primary aldosteronism. Endocrine 77:519–526. https://doi.org/10.1007/S12020-022-03095-8CrossRefPubMedPubMedCentral

10.

Lin YF, Peng KY, Chang CH, Hu YH, Wu VC, Chung SD (2020) Changes in glucose metabolism after adrenalectomy or treatment with a mineralocorticoid receptor antagonist for primary aldosteronism. Endocrinol Metab (Seoul, Korea) 35:838–846. https://doi.org/10.3803/ENM.2020.797CrossRef

11.

Gerards J, Heinrich DA, Adolf C, Meisinger C, Rathmann W, Sturm L et al (2019) Impaired glucose metabolism in primary aldosteronism is associated with cortisol cosecretion. J Clin Endocrinol Metab 104:3192–3202. https://doi.org/10.1210/jc.2019-00299CrossRefPubMed

12.

Araujo-Castro M, Paja Fano M, González Boillos M, Pla Peris B, Pascual-Corrales E, García Cano AM et al (2022) Evolution of the cardiometabolic profile of primary hyperaldosteronism patients treated with adrenalectomy and with mineralocorticoid receptor antagonists: results from the SPAIN-ALDO Registry. Endocrine 76:687–696. https://doi.org/10.1007/s12020-022-03029-4CrossRefPubMed

13.

Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L et al (2019) The REDCap consortium: building an international community of software platform partners. J Biomed Inform 95:103208. https://doi.org/10.1016/j.jbi.2019.103208CrossRefPubMedPubMedCentral

14.

harris Pa, taylor r, thielke r, payne j, gonzalez n, conde jg (2009) research electronic data capture (redcap)-a metadata-driven methodology and workflow process for providing translational research informatics support. j biomed inform 42:377–381. https://doi.org/10.1016/j.jbi.2008.08.010CrossRefPubMed

15.

araujo-castro M, paja fano m, gonzález boillos m, pla peris b, pascual-corrales e, garcía cano am et al (2022) predictive model of hypertension resolution after adrenalectomy in primary aldosteronism: the spain-aldo score. j hypertens 40:2486–2493. https://doi.org/10.1097/hjh.0000000000003284CrossRefPubMed

16.

monticone S, sconfienza e, d’ascenzo f, buffolo f, satoh f, sechi la et al (2020) renal damage in primary aldosteronism: a systematic review and meta-analysis. J Hypertens. https://doi.org/10.1097/HJH.0000000000002216CrossRefPubMed

17.

ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D et al (2023) 2. Classification and diagnosis of diabetes: standards of care in diabetes-2023. Diabetes Care 46:S19–S40. https://doi.org/10.2337/DC23-S002CrossRefPubMed

18.

National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421. https://doi.org/10.1161/circ.106.25.3143.CrossRef

19.

Araujo-Castro M, Sampedro Núñez MA, Marazuela M (2019) Autonomous cortisol secretion in adrenal incidentalomas. Endocrine 64:1–13. https://doi.org/10.1007/s12020-019-01888-yCrossRefPubMed

20.

Williams TA, Lenders JWM, Mulatero P, Burrello J, Rottenkolber M, Adolf C et al (2017) Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 5:689–699. https://doi.org/10.1016/S2213-8587(17)30135-3CrossRefPubMedPubMedCentral

21.

Hanslik G, Wallaschofski H, Dietz A, Riester A, Reincke M, Allolio B et al (2015) Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn’s Registry. Eur J Endocrinol 173:665–675. https://doi.org/10.1530/EJE-15-0450CrossRefPubMed

22.

Kwak MK, Lee JY, Kim BJ, Lee SH, Koh JM (2019) Effects of primary aldosteronism and different therapeutic modalities on glucose metabolism. J Clin Med 8:2194. https://doi.org/10.3390/jcm8122194CrossRefPubMedPubMedCentral

23.

Cole JB, Florez JC (2020) Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol 16:377–390. https://doi.org/10.1038/S41581-020-0278-5CrossRefPubMedPubMedCentral

24.

Ohno Y, Sone M, Inagaki N, Yamasaki T, Ogawa O, Takeda Y et al (2018) Obesity as a key factor underlying idiopathic hyperaldosteronism. J Clin Endocrinol Metab 103:4456–4464. https://doi.org/10.1210/jc.2018-00866CrossRefPubMed

25.

Rossi GP, Belfiore A, Bernini G, Fabris B, Caridi G, Ferri C et al (2008) Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab 93:2566–2571. https://doi.org/10.1210/JC.2008-0251CrossRefPubMed

26.

Spyroglou A, Handgriff L, Müller L, Schwarzlmüller P, Parasiliti-Caprino M, Fuss CT et al (2022) The metabolic phenotype of patients with primary aldosteronism: impact of subtype and sex - a multicenter-study of 3566 Caucasian and Asian subjects. Eur J Endocrinol 187:361–372. https://doi.org/10.1530/EJE-22-0040CrossRefPubMed

27.

Okazaki-Hada M, Moriya A, Nagao M, Oikawa S, Fukuda I, Sugihara H (2020) Different pathogenesis of glucose intolerance in two subtypes of primary aldosteronism: aldosterone-producing adenoma and idiopathic hyperaldosteronism. J Diabetes Investig 11:1511–1519. https://doi.org/10.1111/JDI.13312CrossRefPubMedPubMedCentral

28.

Franch Nadal J, Mata Cases M, Mauricio PD (2016) Epidemiology and clinical management of type 2 diabetes mellitus and associated comorbidities in Spain (e-Management study). Med Clin (Barc) 147(Suppl 1):1–7. https://doi.org/10.1016/S0025-7753(17)30618-8CrossRefPubMed

29.

Monticone S, D’Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F et al (2018) Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 6:41–50. https://doi.org/10.1016/S2213-8587(17)30319-4CrossRefPubMed

30.

Rojo-Martínez G, Valdés S, Soriguer F, Vendrell J, Urrutia I, Pérez V et al (2020) Incidence of diabetes mellitus in Spain as results of the nation-wide cohort di@bet.es study. Sci Rep. https://doi.org/10.1038/s41598-020-59643-7CrossRefPubMedPubMedCentral

31.

Kreze A, Kreze-Spirova E, Mikulecky M (2000) Diabetes mellitus in primary aldosteronism. Bratisl Lek Listy 101:187–190PubMed

32.

Giacchetti G, Ronconi V, Turchi F, Agostinelli L, Mantero F, Rilli S et al (2007) Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens 25:177–186. https://doi.org/10.1097/HJH.0b013e3280108e6fCrossRefPubMed

33.

Moustaki M, Paschou SA, Vakali EC, Vryonidou A (2022) Secondary diabetes mellitus due to primary aldosteronism. Endocrine. https://doi.org/10.1007/s12020-022-03168-8CrossRefPubMed

34.

Nazarzadeh M, Bidel Z, Canoy D, Copland E, Wamil M, Majert J et al (2021) Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. Lancet (London, England) 398:1803–1810. https://doi.org/10.1016/S0140-6736(21)01920-6CrossRefPubMed

35.

Wu VC, Chan CK, Wu WC, Peng KY, Chang YS, Yeh FY et al (2022) New-onset diabetes mellitus risk associated with concurrent autonomous cortisol secretion in patients with primary aldosteronism. Hypertens Res. https://doi.org/10.1038/S41440-022-01086-WCrossRefPubMed

36.

Wu VC, Chueh SCJ, Chen L, Chang CH, Hu YH, Lin YH et al (2017) Risk of new-onset diabetes mellitus in primary aldosteronism: a population study over 5 years. J Hypertens 35:1698–1708. https://doi.org/10.1097/HJH.0000000000001361CrossRefPubMed

37.

Fischer E, Adolf C, Pallauf A, Then C, Bidlingmaier M, Beuschlein F et al (2013) Aldosterone excess impairs first phase insulin secretion in primary aldosteronism. J Clin Endocrinol Metab 98:2513–2520. https://doi.org/10.1210/jc.2012-3934CrossRefPubMed

38.

Tsurutani Y, Sugisawa C, Ishida A, Inoue K, Saito J, Omura M et al (2017) Aldosterone excess may inhibit insulin secretion: a comparative study on glucose metabolism pre- and post-adrenalectomy in patients with primary aldosteronism. Endocr J 64:339–346. https://doi.org/10.1507/ENDOCRJ.EJ16-0500CrossRefPubMed

39.

Bancos I, Alahdab F, Crowley RK, Chortis V, Delivanis DA, Erickson D et al (2016) Improvement of cardiovascular risk factors after adrenalectomy in patients with adrenal tumors and subclinical Cushing’s syndrome: a systematic review and meta-Analysis. Eur J Endocrinol 175:R283–R295. https://doi.org/10.1530/EJE-16-0465CrossRefPubMed

Titel: Prevalence, risk factors and evolution of diabetes mellitus after treatment in primary aldosteronism. Results from the SPAIN-ALDO registry
verfasst von: M. Araujo-Castro
M. Paja Fano
B. Pla Peris
M. González Boillos
E. Pascual-Corrales
A. M. García Cano
P. Parra Ramírez
P. Martín Rojas-Marcos
J. G. Ruiz-Sanchez
A. Vicente Delgado
E. Gómez Hoyos
R. Ferreira
I. García Sanz
M. Recasens Sala
R. Barahona San Millan
M. J. Picón César
P. Díaz Guardiola
C. M. Perdomo
L. Manjón Miguélez
R. García Centeno
J. C. Percovich
Á. Rebollo Román
P. Gracia Gimeno
C. Robles Lázaro
M. Morales-Ruiz
M. Calatayud Gutiérrez
S. A. Furio Collao
D. Meneses
M. A. Sampedro Nuñez
V. Escudero Quesada
E. Mena Ribas
A. Sanmartín Sánchez
C. Gonzalvo Diaz
C. Lamas
R. Guerrero-Vázquez
M. del Castillo Tous
J. Serrano Gotarredona
T. Michalopoulou Alevras
E. M. Moya Mateo
F. A. Hanzu
Publikationsdatum: 10.04.2023
Verlag: Springer International Publishing
Erschienen in: Journal of Endocrinological Investigation / Ausgabe 11/2023
Elektronische ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-023-02090-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Prevalence, risk factors and evolution of diabetes mellitus after treatment in primary aldosteronism. Results from the SPAIN-ALDO registry